CF
YMAB

Corebridge Financial’s Y-mAbs Therapeutics YMAB Stock Holding History

Corebridge Financial’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,305
Closed -$81.1K – 2859
2025
Q1 		$81.1K Sell
18,305
-272
-1% -$1.58K ﹤0.01% 2544
2024
Q4 		$145K Sell
18,577
-1,089
-6% -$13.3K ﹤0.01% 2352
2024
Q3 		$259K Sell
19,666
-121
-0.6% -$1.53K ﹤0.01% 2072
2024
Q2 		$239K Buy
+19,787
New +$267K ﹤0.01% 2085

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Corebridge Financial's YMAB Position: Q2 2025 in Review

Corebridge Financial sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 18,305 shares — an estimated $81.1K sold.

Corebridge Financial first reported a position in YMAB in Q2 2024 and held it in 4 quarters. The position peaked at $259K in Q3 2024. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • Corebridge Financial reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 18,305 Y-mAbs Therapeutics shares in Q2 2025, an estimated $81.1K.
  • Corebridge Financial first reported a position in Y-mAbs Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Y-mAbs Therapeutics position peaked at $259K in Q3 2024.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.